Oncolytic immunotherapy

How Turnstone is combining an oncolytic virus with cancer vaccines

Turnstone Biologics Inc. is combining an oncolytic virus with cancer vaccines, which it anticipates will result in products with efficacy advantages over each individual modality.

Turnstone's origins trace to the Ottawa Hospital Research Institute lab of scientific co-founder John Bell, where two of his postdocs, David Stojdl and Brian Lichty, were studying oncolytic viruses from different angles. The institute is affiliated with the University of Ottawa.

On one track, Stojdl was looking for the most potent oncolytic virus.

"We pored over the literature

Read the full 863 word article

How to gain access

Continue reading with a
two-week free trial.